Have a personal or library account? Click to login
IgA Nephropathy – Current and Future Perspectives in Treatment Cover

IgA Nephropathy – Current and Future Perspectives in Treatment

Acta Medica Martiniana
Volume 24 (2024): Issue 2 (August 2024)
By: Granak Karol,  Vnucak Matej,  Beliancinova Monika,  Kleinova Patricia,  Blichova Timea,  Pytliakova Margareta and  Dedinska Ivana  
Open Access
|Aug 2024

Figures & Tables

Fig. 1

Recommended algorithm for the management of patients with primary IgA nephropathy.*Sparsentan and enteric-coated budesonide are not yet registered in Slovak republic.eGFR, estimated glomerular filtration rate; RAASi, renin angiotensin aldosterone system inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; ACR, albumin creatinine ratio; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker.
DOI: https://doi.org/10.2478/acm-2024-0011 | Journal eISSN: 1338-4139 | Journal ISSN: 1335-8421
Journal RSS Feed
Language: English
Page range: 86 - 91
Submitted on: May 13, 2024
|
Accepted on: Jun 24, 2024
|
Published on: Aug 31, 2024
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 3 issues per year
Keywords:
immunoglobulin A nephropathy,
treatment standards,
future perspectives
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Cardiology

© 2024 Granak Karol, Vnucak Matej, Beliancinova Monika, Kleinova Patricia, Blichova Timea, Pytliakova Margareta, Dedinska Ivana, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 24 (2024): Issue 2 (August 2024)Next article